spacer
home > ebr > winter 2009 > french fulfilment
PUBLICATIONS
European Biopharmaceutical Review

French Fulfilment

Biocitech, a life sciences technology park, has recently announced plans to double its size over the next 10 years. There are already 26 companies established at Biocitech, situated within easy reach of Paris’ city centre and Charles de Gaulle airport.

They represent a wide range of complementary disciplines covering drug discovery, chemistry, computing technology, genetics, non-medicinal health products and various support activities. The pathologies studied include cancer, inflammatory and infectious diseases, diseases of the bones and joints, neurodegenerative diseases and thrombosis. The companies in the park show a track record of consistent success.

They filed more than 30 patent applications in 2007 – a figure which puts Biocitech in third place for the number of filings in the life sciences...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jacques Lhomel is a graduate engineer from the Ecole Centrale de Paris. He began his career as a field engineer in the oil and gas industry where he participated in major contracts abroad (Qatar, Congo and Algeria). After spending 10 years in this sector, he moved on to hold several executive positions, notably in health and beauty care product manufacturing. Jacques joined Aventis in 1998 as Head of COOPER, a subsidiary specialising in distributing products to pharmacists. In 2000, he was appointed CEO of RPG Aventis, the generic drugs business unit of the group, and in 2002 became CEO of Biocitech.
spacer
Jacques Lhomel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Tower’s latest container available for free demonstrations

Tower Cold Chain’s latest product for smaller pharmaceutical shipments, the KTEvolution container offering protection, security, and visibility in a small box, is now available for demonstration globally, at the company’s Centres of Excellence in the EMEA, APAC and Americas regions.
More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement